Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today, according to a press release.

The Horizons Psychedelic Stock Index ETF index will begin trading on Tuesday, January 26, under the ticker symbol PSYK on the NEO exchange.

“We are pleased to be included in the First Psychedelics ETF and being recognized as a leading company in the field of psychedelic pharmaceuticals. We are advancing novel psilocybin-based therapeutics using a proprietary oral thin film delivery technology and a natural biosynthesis enzymatic platform to support clinical research in mental health and substance abuse disorders,” said Michael Frank, CEO of Revive.

Revive is involved in finding therapeutic solutions for rare disorders and infectious diseases. It’s been in building its psychedelics pipeline with a focus on psilocybin based therapeutics using an oral thin film product in collaboration with the University of Wisconsin-Madison. Their present am is to take advantage of several regulatory incentives put forth by the U.S. Food and Drug Administration, including Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. At present, the company is heavily involved in trials involving the use of Bucillamine as a potential treatment for infectious diseases, chief among them COVID-19.

Source: stockwatch.com

Revive is up 10% on the news, and making a strong showing at $.60.
—Joseph Morton
Full disclosure: Revive Therapeutics is an equity guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Shroom Boom
Bucillamine
COVID-19
FDA
Horizons Psychedelic Stock Index ETF
Horizons Psychedelics ETF
magic mushrooms
Psilocybin
psilocybin aided therapies
PSYK.NEO
Revive Therapeutics
RVV.C
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments